Filing Flows › Metagenomi Therapeutics (MGX) › Q1 2025
Metagenomi Therapeutics (MGX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Metagenomi Therapeutics (MGX) reported revenue of $4.1M for the first quarter 2025 (Q1 2025), -63% from a year earlier and -57% from the quarter before. Operating margin was -674.1%, net loss $25.0M (606.7% of revenue).
Metagenomi Therapeutics, Q1 2025: revenue $4.1M (-63% year over year), operating margin -674.1%, net loss $25.0M, operating cash flow −$22.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.1M | -57% | -63% |
| Operating profit | −$27.8M | — | — |
| Net earnings | −$25.0M | — | — |
| Operating cash flow | −$22.8M | — | — |
What changed
Revenue was $4.1M in Q1 2025, down 63% year over year and down 57% from the previous quarter.
Operating costs exceeded revenue by $27.8M, an operating margin of -674.1%. Total costs fell 21% while revenue fell 63%. The quarter ended with a net loss of $25.0M, wider than the previous quarter's $23.4M loss.
Operating cash flow was −$22.8M. Non-cash charges added back $1.4M of depreciation and $2.9M of share-based compensation. Working capital and other items used $2.1M. Capital expenditures of $288K exceeded it, leaving free cash flow of −$23.1M.
Questions
What was Metagenomi Therapeutics' revenue in the first quarter 2025?
Metagenomi Therapeutics (MGX) reported revenue of $4.1M for the first quarter 2025 (Q1 2025), -63% from a year earlier and -57% from the quarter before.
Was Metagenomi Therapeutics profitable in the first quarter 2025?
Operating loss was $27.8M (-674.1% of revenue) and net loss $25.0M.